Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. - Wikidata - wikimedia - TriplyDB

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

http://www.wikidata.org/entity/Q48626253

about

IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.How molecular testing can help (and hurt) in the workup of gliomas.What do we know about IDH1/2 mutations so far, and how do we use it?IDH1 Mutation in Gliomas in Mosul City - Iraq Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.Incorporation of prognostic and predictive factors into glioma clinical trials.Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.Diagnostic immunohistochemistry of canine and feline intracalvarial tumors in the age of brain biopsies.Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Genetic alterations of IDH1 and Vegf in brain tumors.IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report.Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype Something old and something new about molecular diagnostics in gliomas.Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.

P2860

Q33597773-908C7C55-BB40-4B93-AB33-212E39CA0669 Q35051819-0B86CC58-C016-4CB0-AC80-FC5A9562A98E Q35770275-72068547-3190-4D91-B50C-36AA70550E13 Q36788229-6E9E70E6-4E5D-4053-9DED-96647B8F4826 Q36929318-FC46CEBB-9E1E-4A86-BB6A-9BAA2FAE34ED Q37278758-D6448078-FF47-4D87-A0A2-B33CFDBF43E9 Q37407054-48C4AB38-8B23-46A6-BCCC-B4A20BE6CAEE Q37481150-C6C402F2-2173-4C0E-9D95-848AFDF0F575 Q37509161-7F30728D-0F7D-4A44-A120-C8A352E5B352 Q38166556-68C0B34A-F285-4220-AA43-36391621843B Q38260977-E6DB3B04-3813-4469-8AF9-0EDA5D543A0B Q38843549-4FD74029-E643-48C3-BEB4-9D24994EA65B Q41536288-1CDC83B5-D20D-426F-A01F-53C15CA6943F Q41691362-EDC95ACD-DD8C-4CCA-832A-85775BECCF2D Q41721821-56067B87-2F29-404E-B7AA-833804D4AA2D Q42099017-E200F977-AD7A-4A5C-ADCC-B6562C2FAB38 Q42151436-8304713D-C0F9-4C1C-B3AF-490869FD322D Q43238974-97984C8D-A07F-4891-8628-1EF5CB794875 Q45841104-B7F2FDBE-EBBE-4960-AAC9-F2220AF2B60A Q48161149-0D0DAEA1-CBAA-47FE-ADBD-BBFDDF5D293A Q48343949-FC99F7F7-1A20-45AA-AC2E-736DF1C9F678 Q48841420-0F56DC61-288D-4968-A838-02995960B1CB Q55461118-EAEF2117-67FB-4BCF-B4F7-45F176242ADF

P2860

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

http://www.wikidata.org/entity/Q48626253

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Immunohistochemical detection ...... ostic factors of glial tumors.

@en

Immunohistochemical detection ...... ostic factors of glial tumors.

@nl

type

label

Immunohistochemical detection ...... ostic factors of glial tumors.

@en

Immunohistochemical detection ...... ostic factors of glial tumors.

@nl

prefLabel

Immunohistochemical detection ...... ostic factors of glial tumors.

@en

Immunohistochemical detection ...... ostic factors of glial tumors.

@nl

P1433

Q48626253-777F6CA5-3C0F-4B9D-9646-153BB4383BFD

P1476

Q48626253-0348CBD4-76DD-499E-89B6-B9581F1CFB36

P2093

Q48626253-0E37DC24-4517-465D-B95D-F5C5C30754E4

Q48626253-2424AD83-35B0-4C1A-AFD0-07BC90767B50

Q48626253-3346C791-67A8-4B1D-8804-9767F56F5AFE

Q48626253-40DBA823-C0DE-4603-8C3E-C526D11EAE3E

Q48626253-43C249A8-CE9A-4AA0-8DB2-F516E79523E4

Q48626253-4717F48F-B4BD-41D5-AF3D-E86D7AF71B8A

Q48626253-5F9DB87B-5ACB-4FC0-A3BD-656C178B7DC2

Q48626253-7B50C38E-7CA7-417F-A3B2-E2A614B4C75F

Q48626253-9DE941FF-AD90-4869-B7B7-BFFF39EE5184

Q48626253-C7479F44-6127-457C-881E-B24107F4F367

P2860

Q48626253-00176862-8AA3-4BF7-94FD-7715E8F52965

Q48626253-052E3B97-E9E2-42FB-83CA-9B1E5C435FC4

Q48626253-06710055-9B43-4188-BCF8-D6572F39FAE6

Q48626253-07CECC5E-7DAE-44B0-AF77-775644B00F96

Q48626253-14E08E21-122B-4527-A360-92F2EECDEED3

Q48626253-1B9A1FED-3E61-49B7-A0A1-D764F659C63F

Q48626253-2D97BBD8-2D33-4A99-8DA8-ED4BCC9ACB09

Q48626253-2DF6BAD8-5E0F-4F1A-83C6-765AD15EDAE5

Q48626253-2EE7D1FD-23A6-4E41-B117-414A4F98C4A4

Q48626253-3391D5F5-1B70-4BDF-BD53-04FCE5C34F7B

P2888

Q48626253-6EF9E6CE-D536-47D5-9A68-CA340EA85C24

P304

Q48626253-05BD95D4-5E89-4451-A769-C3E8671933B7

P31

Q48626253-355141F9-88AF-48CD-833F-B2E3F27B6E92

P356

Q48626253-753A8F72-BB5D-4B83-8BAB-330782D68966

P433

Q48626253-157C887E-B7CD-48EC-B002-75292FEA9FC5

P478

Q48626253-1523236D-24B3-423F-97F9-71EC7B53F96A

P50

Q48626253-43B63E50-E6C5-45CB-9FF5-1D8540F9F788

P577

Q48626253-EBBB5EFE-66C1-4C9C-8605-DD6FC42AFDB0

P5875

Q48626253-D0B9CEF8-039D-4224-9B16-5A1A1BEB80A7

P698

Q48626253-CB3F31F0-C7F1-4705-8D4C-E70C3828D852

P921

Q48626253-5632F478-C278-4E4D-A52D-F2D02D81FA0E

P356

S11060-012-0837-0

P1433

Journal of Neuro-Oncology

P1476

Immunohistochemical detection ...... nostic factors of glial tumors

@en

P2093

Akira Matsumura

http://www.w3.org/2001/XMLSchema#string

Eiichi Ishikawa

http://www.w3.org/2001/XMLSchema#string

Kei Nakai

http://www.w3.org/2001/XMLSchema#string

Koji Tsuboi

http://www.w3.org/2001/XMLSchema#string

Masahide Matsuda

http://www.w3.org/2001/XMLSchema#string

Mika Kato Kaneko

http://www.w3.org/2001/XMLSchema#string

Ryo Yanagiya

http://www.w3.org/2001/XMLSchema#string

Shingo Takano

http://www.w3.org/2001/XMLSchema#string

Shunpei Morita

http://www.w3.org/2001/XMLSchema#string

Tetsuya Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

IDH1 and IDH2 mutations in gliomas

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Molecular classification of low-grade diffuse gliomas.

Genetic alterations and signaling pathways in the evolution of gliomas.

P2888

s11060-012-0837-0

P304

361-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-012-0837-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221682917

http://www.w3.org/2001/XMLSchema#string

P698

22396072

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry